Hans Erik Johnsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1558516/publications.pdf

Version: 2024-02-01

45 papers	4,732 citations	516561 16 h-index	289141 40 g-index
45 all docs	45 docs citations	45 times ranked	6529 citing authors

#	Article	IF	Citations
1	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission â€“ results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 2022, 22, 147.	1.1	1
2	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. Haematologica, 2021, 106, 1496-1499.	1.7	9
3	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. Journal of Clinical Oncology, 2020, 38, 3252-3260.	0.8	102
4	High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. Journal of Infectious Diseases, 2019, 220, 1312-1324.	1.9	13
5	A B-cellâ€“associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology. Blood Advances, 2018, 2, 1542-1546.	2.5	13
6	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. Blood, 2018, 132, 3186-3186.	0.6	3
7	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow â€“ A proof of concept study. PLoS ONE, 2018, 13, e0193249.	1.1	8
8	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. Journal of Clinical Oncology, 2017, 35, 778-784.	0.8	72
9	Molecular classification of tissue from a transformed non-Hogkinâ€™s lymphoma case with unexpected long-time remission. Experimental Hematology and Oncology, 2017, 6, 3.	2.0	2
10	Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival. Leukemia and Lymphoma, 2017, 58, 2695-2704.	0.6	11
11	Anthropometrics and prognosis in diffuse large Bâ€cell lymphoma: a multicentre study of 653 patients. European Journal of Haematology, 2017, 98, 355-362.	1.1	2
12	A systematic review of molecular responses to cancer therapy in normal human mucosa. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 355-366.	0.2	3
13	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. Leukemia and Lymphoma, 2017, 58, 1105-1113.	0.6	26
14	miR-155 as a Biomarker in B-Cell Malignancies. BioMed Research International, 2016, 2016, 1-14.	0.9	56
15	hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. PLoS ONE, 2016, 11, e0163711.	1.1	7
16	The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica, 2016, 101, 1451-1459.	1.7	55
17	The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines. Biomarker Research, 2016, 4, 12.	2.8	29
18	Characterization of memory B cells from thymus and its impact for DLBCL classification. Experimental Hematology, 2016, 44, 982-990.e11.	0.2	3

#	Article	IF	Citations
19	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. Experimental Hematology, 2016, 44, 238-246.e2.	0.2	46
20	Long Noncoding RNA Expression during Human B-Cell Development. PLoS ONE, 2015, 10, e0138236.	1.1	80
21	Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer, 2015, 15, 235.	1.1	44
22	Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 3257-3266.	0.6	7
23	Outcome prediction by extranodal involvement, IPI, Râ€IPI, and NCCNâ€IPI in the PET/CT and rituximab era: A <scp>D</scp>anishâ€“<scp>C</scp>anadian study of 443 patients with diffuseâ€large <scp>B</scp>â€cell lymphoma. American Journal of Hematology, 2015, 90, 1041-1046.	2.0	71
24	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	1.7	289
25	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
26	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danishâ€“Swedish Population-Based Study. Journal of Clinical Oncology, 2015, 33, 3993-3998.	0.8	74
27	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2015, 126, 3905-3905.	0.6	1
28	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. Blood, 2015, 126, 4146-4146.	0.6	2
29	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. PLoS ONE, 2015, 10, e0116966.	1.1	10
30	Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkinâ€™s Lymphoma Risk and Survival. PLoS ONE, 2015, 10, e0139329.	1.1	7
31	MicroRNAs in B-cells: from normal differentiation to treatment of malignancies. Oncotarget, 2015, 6, 7-25.	0.8	24
32	Subtyping of B-Cell Malignancies By B-Cell Subset Associated Gene Signatures (BAGS), Generated from Human Primary and Secondary Lymphoid Organs.. Blood, 2015, 126, 5347-5347.	0.6	0
33	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica, 2014, 99, 984-996.	1.7	124
34	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Experimental Hematology, 2014, 42, 927-938.	0.2	15
35	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	5.1	3,343
36	Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. BMC Immunology, 2014, 15, 3.	0.9	10

#	Article	IF	Citations
37	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2014, 124, 35-35.	0.6	11
38	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. Blood, 2014, 124, 1630-1630.	0.6	1
39	Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.. Blood, 2012, 120, 2637-2637.	0.6	0
40	Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity. Blood, 2012, 120, 4010-4010.	0.6	0
41	Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients. Blood, 2012, 120, 1532-1532.	0.6	0
42	Gene Expression Profiling of Murine T-Cell Lymphoblastic Lymphoma Identifies Deregulation of S-Phase Initiating Genes.. Blood, 2012, 120, 2395-2395.	0.6	4
43	Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis In Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan. Blood, 2010, 116, 904-904.	0.6	5
44	Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.. Blood, 2009, 114, 107-107.	0.6	3
45	Impact of Growth Factor Independence 1 in Human T-Cell Lymphomas; Pathogenic Potential Identified by Insertional Mutagenesis in a Murine T-Cell Lymphoma Model.. Blood, 2009, 114, 5047-5047.	0.6	0